RTW INVESTMENTS, LPRTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q1 2026

Top Holdings88 positions

Checking export access…
Activity:

MADRIGAL PHARMACEUTICALS INC

2M$1B10.4%$265.94+96.84%
12 qtrssince 2023-Q2
Unchanged
0

INSMED INC

4.8M$791.9M7.9%$92.32+77.11%
12 qtrssince 2023-Q2
Increased
61

PROTAGONIST THERAPEUTICS INC

5.1M$533.2M5.3%$24.30+333.75%
27 qtrssince 2019-Q3
Unchanged
0

PTC THERAPEUTICS INC

7.7M$527.8M5.3%$43.73+47.24%
29 qtrssince 2019-Q1
Unchanged
0
ARGXARGX
ADR

ARGENX SE

709,446$518.1M5.2%$374.99+94.74%
29 qtrssince 2019-Q1
Increased
64

CG ONCOLOGY INC

7M$472.7M4.7%$53.16+13.91%
9 qtrssince 2024-Q1
Increased
93

CELCUITY INC

3M$346.9M3.5%$106.05+1.28%
2 qtrssince 2025-Q4
Increased
92

TANGO THERAPEUTICS INC

13.3M$278.2M2.8%$11.18+2.88%
2 qtrssince 2025-Q4
Increased
85

ERASCA INC

16.2M$261.4M2.6%$14.00+0.68%
2 qtrssince 2025-Q4
Increased
85

NATERA INC

1.3M$250M2.5%$42.81+367.17%
27 qtrssince 2019-Q3
Decreased
0

RADNET INC

4.3M$239.5M2.4%$55.90-0.03%
10 qtrssince 2023-Q4
Increased
57

TARSUS PHARMACEUTICALS INC

3.3M$234.7M2.3%$36.18+111.61%
22 qtrssince 2020-Q4
Increased
53
APGEAPGEDelisted

APOGEE THERAPEUTICS INC

2.8M$234.2M2.3%——
11 qtrssince 2023-Q3
Increased
54

SPYRE THERAPEUTICS INC

4.2M$210.4M2.1%$23.64+113.33%
10 qtrssince 2023-Q4
Unchanged
0

COGENT BIOSCIENCES INC

5.5M$210.1M2.1%$25.86+48.86%
3 qtrssince 2025-Q3
Decreased
0

IRHYTHM HOLDINGS INC

1.7M$196.9M2.0%$160.11-26.29%
2 qtrssince 2025-Q4
Increased
64

STOKE THERAPEUTICS INC

5.6M$183.1M1.8%$23.85+41.66%
28 qtrssince 2019-Q2
Increased
49

CYTOKINETICS INC

2.7M$179.4M1.8%$28.96+127.58%
23 qtrssince 2020-Q3
Unchanged
0

ACADIA PHARMACEUTICALS INC

7.1M$159M1.6%$18.51+20.25%
16 qtrssince 2022-Q2
Unchanged
0

ESTABLISHMENT LABS HOLDINGS INC

2.7M$150.8M1.5%$27.61+105.67%
29 qtrssince 2019-Q1
Increased
49
$10B
AUM
88
Positions
Q1 2026
Filing
HI score · 2.0/5
Quarterly 13F Value Change
-4%Q4'24$6.6B-1%Q1'25$6.5B+7%Q2'25$7B+16%Q3'25$8.1B+23%Q4'25$10B+1%Q1'26$10B
Activity profile
$ moved · Q1'26
New6%Increased57%Decreased13%Exited24%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.5 years
<1Q9%1-4Q31%1-2Y14%2Y+47%

RTW INVESTMENTS, LP manages $10B across 88 positions as of Q1 2026. Top holdings: MDGL (10.4%), INSM (7.9%), PTGX (5.3%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2/5.0.

Q1 2026 Summary

Active quarter - 9 new positions, 12 exits, 30 increased. Top move: CGON (INCREASED, conviction 93). Portfolio: $10.0B across 88 positions.

Top holdings by portfolio weight

Total AUM$10B
MDGL10.38%
INSM7.88%
PTGX5.31%
PTCT5.25%
ARGX5.16%
CGON4.70%
CELC3.45%
TNGX2.77%
ERAS2.60%
NTRA2.49%
Other2.38%

Portfolio allocation by GICS sector

Sectors2
Healthcare99.92%
Financial Services0.08%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(2.0 / 5.0)
Holdings P&L48
Conviction44
Concentration72
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
RDNTRDNTRADNET INC
Q4 2024 → Q2 2026+3M shares+$173.4M
6Q
CMPSCMPSCOMPASS PATHWAYS PLC
Q1 2025 → Q2 2026+7.6M shares+$139.7M
6Q
IMTXIMTXIMMATICS N.V
Q1 2025 → Q2 2026+6.4M shares+$84.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used